<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144910</url>
  </required_header>
  <id_info>
    <org_study_id>KGU-317/09</org_study_id>
    <nct_id>NCT01144910</nct_id>
  </id_info>
  <brief_title>The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children</brief_title>
  <acronym>BHR</acronym>
  <official_title>A Prospective, Open Label, Single-center Study of the Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of investigator´s clinical trial is to investigate 52 patients aged three to five
      years with viral-induced asthma and 52 patients aged three to five years with allergic
      asthma. Over a time-span of 5 years the investigators will explore lung function and
      bronchial responsiveness. The investigators plan to evaluate long-term clinical history of
      moderate to severe bronchial hyperresponsiveness in preschool children with asthma. Therefore
      factors like atopy in children, parental atopy and bronchial hyperresponsiveness will be
      explored.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A positive family history with prevalence of atopy, eczema, wheezing are well-known factors
      predicting asthma. Caudri et al. found more important predictors like perinatal transmission,
      parental use of inhalative medications and wheezing/dyspnea out of viral infections(5).
      Measurement of BHR in children was in most studies a second outcome parameter.

      Four visits will be performed, baseline and after 1, 3, and 5 years. At visit 1 the
      investigators will characterize all patients by a ISAAC survey. At each visit in children a
      methacholine challenge, a skin Prick test, eNO, RAST and total IgE will be performed. At
      visit 3 and 4 sputum will be induced. In parents only at the first visit a methacholine
      challenge will be performed. A genetic identification of ADAM33 gene from EDTA blood shall be
      provided. ADAMs are multidomain proteins with a metalloprotease domain, associated with
      airway remodelling. Visits should be kept in a time interval without asthma therapy and
      respiratory infection.

      To examine the feasibility of methacholine challenges in preschool children data measured in
      2006 will be analysed.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to few capacities 2011 to 2016 the study was withdrawn.
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of severe bronchial hyperresponsiveness over time of five years.</measure>
    <time_frame>five years</time_frame>
    <description>Bronchial hyperresponsiveness will be defined by the provocation dose (PD) of methacholine causing a 20% drop of FEV1 (PD-20FEV1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchial responsiveness of parents</measure>
    <time_frame>two years</time_frame>
    <description>In parents at first visit bronchial hyperresponsiveness will be defined by the provocation dose (PD) of methacholine causing a 20% drop of FEV1 (PD-20FEV1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of atopy</measure>
    <time_frame>five years</time_frame>
    <description>Influence of atopy on the time course of bronchial hyperresponsiveness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eNO</measure>
    <time_frame>five years</time_frame>
    <description>Influence of the level of exhaled NO on the time course of BHR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total-IgE</measure>
    <time_frame>five years</time_frame>
    <description>Influence of the level of total-IgE on the time course of BHR</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Intrinsic Asthma</condition>
  <condition>Allergic Asthma</condition>
  <condition>Allergy</condition>
  <condition>Bronchial Hyperresponsiveness</condition>
  <arm_group>
    <arm_group_label>BHR non-atopy</arm_group_label>
    <description>Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BHR atopy</arm_group_label>
    <description>Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>methacholine challenge test</intervention_name>
    <description>2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.
the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.</description>
    <arm_group_label>BHR non-atopy</arm_group_label>
    <other_name>There are no other names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>methacholine challenge test</intervention_name>
    <description>2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.
the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.</description>
    <arm_group_label>BHR atopy</arm_group_label>
    <other_name>There are no other names.</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, sputum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients from the outpatient Department of Allergology, Pneumology and Cystic fibrosis,
        children's hospital, Goethe-University, Frankfurt, Germany
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  age 3 to 6 years

          -  diagnosis asthma

          -  pulmonary function: FEV1 (% pred.)≥ 70%

          -  ability to carry out 2 reproducible flow volume loops

          -  moderate to severe BHR (PD20 FEV1 ≤ 0,3 mg methacholine)

          -  more than 4 weeks interval since last infection

          -  8 hours washout period of Short Acting Beta Agonist

          -  1 week washout period of Ipratropium Bromide

          -  1 week washout period of Long Acting Beta Agonist

          -  4 weeks washout period of Systemic Corticosteroids

          -  4 weeks washout period of Leukotriene Antagonists

        Exclusion Criteria:

          -  Age &lt; 3 and &gt; 6 Years

          -  Pulmonary function test: FEV1 (% pred.) &lt; 70%

          -  Others chronic diseases or infections (e.g., HIV, tuberculosis, malignancy)

          -  Incapability to perform spirometry

          -  Current participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Schulze, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Goethe University</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, Mitchell EA, Pearce N, Sibbald B, Stewart AW, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J. 1995 Mar;8(3):483-91.</citation>
    <PMID>7789502</PMID>
  </reference>
  <reference>
    <citation>Castro-Rodríguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1403-6.</citation>
    <PMID>11029352</PMID>
  </reference>
  <reference>
    <citation>Frank PI, Morris JA, Hazell ML, Linehan MF, Frank TL. Long term prognosis in preschool children with wheeze: longitudinal postal questionnaire study 1993-2004. BMJ. 2008 Jun 21;336(7658):1423-6. doi: 10.1136/bmj.39568.623750.BE. Epub 2008 Jun 16.</citation>
    <PMID>18558639</PMID>
  </reference>
  <reference>
    <citation>Matricardi PM, Illi S, Grüber C, Keil T, Nickel R, Wahn U, Lau S. Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence. Eur Respir J. 2008 Sep;32(3):585-92. doi: 10.1183/09031936.00066307. Epub 2008 May 14.</citation>
    <PMID>18480107</PMID>
  </reference>
  <reference>
    <citation>Caudri D, Wijga A, A Schipper CM, Hoekstra M, Postma DS, Koppelman GH, Brunekreef B, Smit HA, de Jongste JC. Predicting the long-term prognosis of children with symptoms suggestive of asthma at preschool age. J Allergy Clin Immunol. 2009 Nov;124(5):903-10.e1-7. doi: 10.1016/j.jaci.2009.06.045. Epub 2009 Aug 8.</citation>
    <PMID>19665765</PMID>
  </reference>
  <reference>
    <citation>Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med. 2005 Oct 1;172(7):831-6. Epub 2005 Jun 23.</citation>
    <PMID>15976380</PMID>
  </reference>
  <reference>
    <citation>Illi S, von Mutius E, Lau S, Niggemann B, Grüber C, Wahn U; Multicentre Allergy Study (MAS) group. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet. 2006 Aug 26;368(9537):763-70. Erratum in: Lancet. 2006 Sep 30;368(9542):1154.</citation>
    <PMID>16935687</PMID>
  </reference>
  <reference>
    <citation>Nuijsink M, Hop WC, Sterk PJ, Duiverman EJ, de Jongste JC. Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial. Eur Respir J. 2007 Sep;30(3):457-66. Epub 2007 May 30.</citation>
    <PMID>17537770</PMID>
  </reference>
  <reference>
    <citation>Beydon N. Pulmonary function testing in young children. Paediatr Respir Rev. 2009 Dec;10(4):208-13. doi: 10.1016/j.prrv.2009.03.001. Epub 2009 Sep 25. Review.</citation>
    <PMID>19879511</PMID>
  </reference>
  <reference>
    <citation>Beydon N. Assessment of bronchial responsiveness in preschool children. Paediatr Respir Rev. 2006;7 Suppl 1:S23-5. Epub 2006 Jun 5. Review.</citation>
    <PMID>16798575</PMID>
  </reference>
  <reference>
    <citation>Holgate ST, Davies DE, Powell RM, Howarth PH, Haitchi HM, Holloway JW. Local genetic and environmental factors in asthma disease pathogenesis: chronicity and persistence mechanisms. Eur Respir J. 2007 Apr;29(4):793-803. Review.</citation>
    <PMID>17400878</PMID>
  </reference>
  <reference>
    <citation>Schulze J, Rosewich M, Riemer C, Dressler M, Rose MA, Zielen S. Methacholine challenge--comparison of an ATS protocol to a new rapid single concentration technique. Respir Med. 2009 Dec;103(12):1898-903. doi: 10.1016/j.rmed.2009.06.007. Epub 2009 Jul 10.</citation>
    <PMID>19596563</PMID>
  </reference>
  <reference>
    <citation>Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000 Jan;161(1):309-29.</citation>
    <PMID>10619836</PMID>
  </reference>
  <reference>
    <citation>Hagmolen of ten Have W, van den Berg NJ, van der Palen J, Bindels PJ, van Aalderen WM. Validation of a single concentration methacholine inhalation provocation test (SCIPT) in children. J Asthma. 2005 Jul-Aug;42(6):419-23.</citation>
    <PMID>16293536</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Johannes Schulze MD</investigator_full_name>
    <investigator_title>Cosultant, Pediadric Allergy, Pulmonology and Cystic fibrosis</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>preschool child</keyword>
  <keyword>bronchial hyperresponsiveness</keyword>
  <keyword>methacholine challenge test</keyword>
  <keyword>atopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Bronchial Hyperreactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

